- Home
- NMI vs NRXP Comparison
NMI vs NRXP Comparison
Compare NMI & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMI | NRXP |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.6M | 99.2M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | NMI | NRXP |
|---|---|---|
| Price | $11.04 | $4.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.25 |
| AVG Volume (30 Days) | 14.4K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,547.84 |
| Revenue Next Year | N/A | $1,591.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.62 | $1.65 |
| 52 Week High | $11.28 | $5.06 |
Technical Indicators
Market Signals| Indicator | NMI | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 57.47 | 55.01 |
| Support Level | $9.88 | $1.83 |
| Resistance Level | $11.23 | $5.06 |
| Average True Range (ATR) | 0.21 | 0.35 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 66.67 | 32.40 |
Price Performance
Historical ComparisonAbout NMI Nuveen Municipal Income Fund Inc.
Nuveen Municipal Income Fund Inc is a diversified, closed-end management investment company. The Fund's investment objective is to provide a high level of current income exempt from federal income tax, which it seeks to achieve by investing mainly in a diversified portfolio of tax-exempt municipal obligations.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.